Weight Loss Peptides Canada
Retatrutide and Tesamorelin represent the leading edge of metabolic peptide research. Retatrutide simultaneously targets GIP, GLP-1, and glucagon receptors — producing up to 24% body weight reduction in Phase 2 trials. Tesamorelin, an FDA-approved GHRH analogue, drives visceral fat reduction through physiological growth hormone stimulation. Both independently tested to 99%+ purity and shipped within Canada.
Metabolic Peptide Research
Retatrutide
Retatrutide (LY3437943) is an investigational triple agonist developed by Eli Lilly that simultaneously targets GLP-1, GIP, and glucagon receptors. The Phase 2 TRIUMPH trial demonstrated up to 24.2% body weight reduction at 48 weeks — the highest figure recorded for any pharmacological agent in a clinical trial. The added glucagon component drives energy expenditure beyond what dual agonists achieve.
Read the Retatrutide guide →Tesamorelin
Tesamorelin is a 44-amino-acid synthetic GHRH analogue that holds FDA approval for visceral fat reduction in HIV-associated lipodystrophy — one of the few research peptides with a full Phase 3 human dataset. It stimulates endogenous growth hormone release in physiological pulses, preserving the hypothalamic feedback loop and avoiding sustained insulin resistance associated with exogenous GH.
Read the Tesamorelin guide →Research use only. All products sold by JA Performance are strictly for laboratory and in vitro research purposes. Not for human consumption, medical use, or veterinary use.